{
    "@graph": [
        {
            "@id": "gnd:4136401-6",
            "sameAs": "Wachstumshemmung"
        },
        {
            "@id": "gnd:4143176-5",
            "sameAs": "Arzneimittelentwicklung"
        },
        {
            "@id": "gnd:7501248-0",
            "sameAs": "MRSA"
        },
        {
            "@id": "https://www.tib.eu/de/suchen/id/TIBKAT%3A766432718",
            "@type": "bibo:Thesis",
            "P1053": "Online-Ressource (318 Bl. = 6,35 mb)",
            "http://purl.org/dc/elements/1.1/contributor": [
                "Suzen, Sibel",
                "Hilgeroth, Andreas",
                "Lalk, Michael"
            ],
            "creator": "El-Sayed, Mardia El-Dessoky Teleb",
            "identifier": [
                "(firstid)GBV:766432718",
                "(ppn)766432718",
                "(doi)10.25673/949"
            ],
            "publisher": "Universit\u00e4ts- und Landesbibliothek Sachsen-Anhalt",
            "http://purl.org/dc/elements/1.1/subject": [
                "(classificationName=ddc-dbn)540",
                "(classificationName=linseach:mapping)meda",
                "(classificationName=linseach:mapping)cet",
                "(classificationName=bk, id=106422030)44.43 - Medizinische Mikrobiologie",
                "(classificationName=bk, id=106417622)58.28 - Pharmazeutische Technologie",
                "(classificationName=ddc-dbn)615"
            ],
            "title": "Development of novel indolyl-derived biologically active compounds",
            "abstract": [
                "MRSA; superbug; antibiotics resistance; bactericidal agents; cycloalkanoindoles; bis-indolobenzocarbazoles; oxidized bis-indolylmethenes; gram-positive pathogens",
                "MRSA ist ein methicillin resistenter Staphylococcus Bakterienstamm, welcher Resistenzen gegen die Wirkung von \u03b2-Lactam Antibiotika entwickelt hat, mitunter die Penicilline Methicillin, Dicloxacillin, Nafcillin, Oxacillin und weitere. Der Staphylococcus Stamm im Allgemeinen ist f\u00fcr eine Vielzahl an Infektionen im Bereich Haut, Lunge und anderen Regionen verantwortlich. MRSA wird manchmal auch als \u201esuperbug\u201c bezeichnet, weil es schlecht behandelbar ist und wegen seiner Resistenz gegen viele Antibiotika j\u00e4hrlich eine hohe Zahl an Infektionen in Krankenh\u00e4usern ausl\u00f6st. Rund 19.000 Menschen sterben laut einer statistischen Auswertung (CDC) jedes Jahr an einer MRSA-Infektionen allein in den USA. Eine erw\u00e4hnenswerte neue Erg\u00e4nzung zu unserem antibakteriellen Arsenal gegen MRSA-Infektionen w\u00e4ren neue bakterizide Stoffe gegen resistente Isolate und Standards. Wir haben erstmals gezeigt, dass Cycloalkanindole, bis-Indolobenzocarbazole und oxidierte bis-Indolylmethene eine hemmende Wirkung auf das Wachstum der resistenten MRSA (Standard und Isolate) und andere gram-positive Bakterien bei niedrigen Konzentrationen haben. Diese neuartigen, hier beschriebenen bis- und tris-Indolyl-Inhibitoren k\u00f6nnen einfach und kosteng\u00fcnstig synthetisiert werden und strukturelle Modifikationen, um die in vitro Aktivit\u00e4t zu verbessern, effizient erreicht werden. Im Zusammenhang mit der Entwicklung neuer Medikamente zur Bek\u00e4mpfung des MRSA und anderer gram-positiver Keime sind dies signifikante Ergebnisse.",
                "MRSA; superbug; Antibiotikaresistenz; bakterizide Mittel; Cycloalkanindole; bis-Indolobenzocarbazole; oxidierte bis-Indolylmethene; gram-positive Erreger",
                "MRSA is a methicillin-resistance Staphylococcus aureus and a strain of Staphylococcus aureus that developed resistance to the killing effect of the \u03b2-lactam antibiotics, which include the penicillins (methicillin, dicloxacillin, nafcillin, oxacillin, etc.) This strain of common \u201cstaph\u201d bacteria causes infections in different parts of the body including the skin, lung and other areas. MRSA is sometimes called a \u201csuperbug\u201d because it is very difficult to treat and it causes a huge number of infections every year in hospitals all over the world due to the resistance to many antibiotics. Statistical data (CDC) suggest that as many as 19,000 people per year have died from MRSA in the USA. A valuable new addition to our antibacterial arsenal for MRSA infections would be new bactericidal agents effective against resistant isolates or standard. We have shown for the first time that the cycloalkanoindoles, bis-indolobenzocarbazoles and the oxidized bis-indolylmethenes inhibited growth of drug resistant MRSA either standard or isolate and other Gram-positive bacteria at low concentrations. These novel bis- and tris-indolyl inhibitors described here can be synthesized easily and cost-effectively and structural modifications to improve the inhibitory activity in vitro can be achieved in a time efficient manner. The results are expected to be of significance in terms of discovering new molecules that can be developed into drugs to combat MRSA and gram-positive pathogens."
            ],
            "contributor": "Technische Informationsbibliothek (TIB)",
            "isPartOf": "(collectioncode)GBV-ODiss",
            "issued": "2013",
            "language": "http://id.loc.gov/vocabulary/iso639-1/de",
            "license": "commercial licence",
            "medium": "rda:termList/RDACarrierType/1018",
            "subject": [
                "gnd:4143176-5",
                "gnd:4136401-6",
                "gnd:7501248-0"
            ],
            "isLike": "doi:10.25673/949"
        }
    ],
    "@id": "urn:x-arq:DefaultGraphNode",
    "@context": {
        "sameAs": "http://www.w3.org/2002/07/owl#sameAs",
        "abstract": "http://purl.org/dc/terms/abstract",
        "subject": {
            "@id": "http://purl.org/dc/terms/subject",
            "@type": "@id"
        },
        "contributor": "http://purl.org/dc/terms/contributor",
        "license": "http://purl.org/dc/terms/license",
        "language": {
            "@id": "http://purl.org/dc/terms/language",
            "@type": "@id"
        },
        "identifier": "http://purl.org/dc/elements/1.1/identifier",
        "title": "http://purl.org/dc/elements/1.1/title",
        "isLike": {
            "@id": "http://umbel.org/umbel#isLike",
            "@type": "@id"
        },
        "publisher": "http://purl.org/dc/elements/1.1/publisher",
        "P1053": "http://iflastandards.info/ns/isbd/elements/P1053",
        "issued": "http://purl.org/dc/terms/issued",
        "medium": {
            "@id": "http://purl.org/dc/terms/medium",
            "@type": "@id"
        },
        "isPartOf": "http://purl.org/dc/terms/isPartOf",
        "creator": "http://purl.org/dc/elements/1.1/creator",
        "umbel": "http://umbel.org/umbel#",
        "rdau": "http://www.rdaregistry.info/Elements/u/#",
        "owl": "http://www.w3.org/2002/07/owl#",
        "dcterms": "http://purl.org/dc/terms/",
        "bibo": "http://purl.org/ontology/bibo/",
        "rdam": "http://www.rdaregistry.info/Elements/m/#",
        "gnd": "http://d-nb.info/gnd/",
        "isbd": "http://iflastandards.info/ns/isbd/elements/",
        "rda": "http://rdvocab.info/",
        "doi": "https://doi.org/"
    }
}